NP 002

Drug Profile

NP 002

Alternative Names: NP-002

Latest Information Update: 21 Sep 2015

Price : $50

At a glance

  • Originator Neuraltus Pharmaceuticals
  • Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Drug-induced dyskinesia

Most Recent Events

  • 07 Dec 2010 Top-line safety and efficacy data from a phase I/II trial in Drug-induced dyskinesia released by Neuraltus
  • 01 Oct 2009 Phase-I/II clinical trials in Drug-induced dyskinesia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top